Shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO) have been given a consensus rating of “Buy” by the sixteen ratings firms that are presently covering the firm, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $93.67.
AGIO has been the subject of several recent research reports. ValuEngine raised Agios Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 2nd. UBS Group cut Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 14th. SunTrust Banks reissued a “buy” rating and set a $101.00 price objective (up from $80.00) on shares of Agios Pharmaceuticals in a report on Thursday, February 15th. Needham & Company LLC boosted their price objective on Agios Pharmaceuticals from $72.00 to $86.00 and gave the stock a “buy” rating in a report on Thursday, February 15th. Finally, Credit Suisse Group set a $95.00 price objective on Agios Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, April 11th.
In other news, insider Christopher Bowden sold 2,000 shares of the company’s stock in a transaction dated Thursday, April 12th. The stock was sold at an average price of $85.10, for a total value of $170,200.00. Following the completion of the sale, the insider now directly owns 2,881 shares of the company’s stock, valued at approximately $245,173.10. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Scott Biller sold 3,000 shares of the company’s stock in a transaction dated Tuesday, June 5th. The shares were sold at an average price of $93.37, for a total value of $280,110.00. Following the completion of the sale, the insider now directly owns 60,196 shares of the company’s stock, valued at $5,620,500.52. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 171,077 shares of company stock valued at $15,096,769. 3.02% of the stock is currently owned by company insiders.
NASDAQ AGIO traded up $1.89 on Thursday, hitting $94.19. 2,297 shares of the company were exchanged, compared to its average volume of 506,758. The company has a market cap of $5.35 billion, a price-to-earnings ratio of -14.03 and a beta of 2.00. Agios Pharmaceuticals has a 1-year low of $49.76 and a 1-year high of $97.59.
Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Friday, May 4th. The biopharmaceutical company reported ($1.63) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.60) by ($0.03). The company had revenue of $8.80 million for the quarter, compared to analyst estimates of $11.93 million. Agios Pharmaceuticals had a negative return on equity of 61.70% and a negative net margin of 822.32%. The firm’s quarterly revenue was down 16.2% on a year-over-year basis. During the same quarter last year, the company earned ($1.56) EPS. research analysts predict that Agios Pharmaceuticals will post -6.51 earnings per share for the current year.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.